{"id":"albiglutide-insulin-glargine","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Injection site reactions"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Muscle pain"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Nasopharyngitis"},{"rate":"5-10%","effect":"Upper respiratory tract infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Albiglutide works by binding to GLP-1 receptors in the pancreas, stimulating insulin release in response to elevated glucose levels. Insulin glargine, on the other hand, is a modified form of human insulin that is designed to be released slowly and steadily over a 24-hour period, providing a basal level of insulin to help control blood sugar levels.","oneSentence":"Albiglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that enhances glucose-dependent insulin secretion, and insulin glargine is a long-acting basal insulin analog that provides a steady level of insulin throughout the day.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:21.150Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT02787551","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-06","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT02229227","phase":"PHASE3","title":"Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-11-21","conditions":"Diabetes Mellitus, Type 2","enrollment":814},{"nctId":"NCT02846233","phase":"NA","title":"Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2016-08","conditions":"Type 2 Diabetes Mellitus","enrollment":22},{"nctId":"NCT00976391","phase":"PHASE3","title":"A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09","conditions":"Diabetes Mellitus, Type 2","enrollment":586},{"nctId":"NCT00838916","phase":"PHASE3","title":"A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02","conditions":"Diabetes Mellitus, Type 2","enrollment":779}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"albiglutide + insulin glargine","genericName":"albiglutide + insulin glargine","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"Albiglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that enhances glucose-dependent insulin secretion, and insulin glargine is a long-acting basal insulin analog that provides a steady level of insulin throughout the day. Used for Type 2 diabetes mellitus, Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}